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merging lung infections 
capture the world’s imagination 
because of the potential for 
pandemics. Recent examples include 
avian inﬂ  uenza and the severe 
acute respiratory syndrome (SARS). 
However, even in the absence of 
new pathogens or pandemics, lung 
infections have tremendous impact. 
Lung infections cause more disease 
than better-recognized threats to 
the public’s health such as cancer, 
heart attacks, strokes, HIV/AIDS, 
tuberculosis, or malaria. This persistent 
and pervasive burden of lung infections 
receives proportionately little attention 
from the biomedical and public health 
communities.
The Global Burden of Lung 
Infections
The Burden of Disease Project [1] 
at the World Health Organization 
(WHO) collects statistics that can be 
used to determine the public health 
impact of different diseases. The 
metric of disability-adjusted life years 
(DALYs) lost takes into account the 
amount of otherwise healthy life lost to 
morbidity and/or mortality. Diseases 
were categorized according to the 
International Classiﬁ  cation of Diseases 
(ICD) from WHO [2].
The “lung infections” category 
includes “Inﬂ  uenza and pneumonia” 
(ICD–10 codes J10–18) and “Other 
acute lower respiratory infections” 
(ICD–10 J20–22), but it excludes 
“Tuberculosis” (ICD–10 A15–19) and 
“HIV disease resulting in infectious 
and parasitic diseases” (ICD–10 B20). 
By excluding respiratory tuberculosis 
as well as pneumonias in patients with 
HIV/AIDS, these statistics might be 
considered by some to underestimate 
the burden of disease due to lung 
infections. Even with those exclusions, 
lung infections accounted for more 
than 6% of the total global burden of 
disease in 2002. This disease burden 
is greater than that of other better-
recognized causes 
of disease (Figure 
1). This impressive 
burden is not an 
anomaly of that 
particular year, 
due to SARS or 
any other unusual 
epidemic or event, 
but is instead the 
norm. Since 1990, 
when WHO began 
compiling and 
presenting such 
statistics, lung 
infections have 
consistently caused 
more burden than 
any of the diseases 
identiﬁ  ed in Figure 
1 [3,4].
The 
Disproportionate 
Burden 
on the Poor
Lung infections are 
especially common 
and severe among 
the poor. When 
the relative burden 
of disease in communities is assessed 
by normalizing DALYs to population 
size, lung infections caused the loss 
of 2,983 DALYs/100,000 population 
in the poorest regions compared to 
137 DALYs/100,000 population in the 
wealthiest. Thus, poverty is associated 
with a more than 20-fold increase in 
the relative burden of lung infections.
According to WHO, 2.6 billion 
people live in “Low Income” countries, 
with Gross National Income (GNI) 
per capita ≤US$765, and 2.2 billion 
people live in “Lower Middle 
Income” countries, with GNI per 
capita of US$766–US$3,035. This 
single incremental improvement in 
income is associated with a dramatic 
difference in the relative burden of 
disease caused by lung infections. 
Lung infections caused the loss of 535 
DALYs per 100,000 population in the 
“Lower Middle Income” population 
in 2002. Comparing this ﬁ  gure to the 
relevant ﬁ  gures listed above, it may be 
surmised that the vast majority (86%) 
of the difference due to income occurs 
between the lowest income group 
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Figure 1. The Global Burden of Selected Diseases in 2002, as 
Measured by Disability-Adjusted Life Years (DALYs) Lost Worldwide
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and the next-to-lowest income group. 
Thus, the poor are especially likely 
to suffer from lung infections, and 
relatively modest income improvements 
may substantially lessen their burden 
of lung infection. As with many 
infectious diseases [5], ﬁ  ghting poverty 
and improving health care for the 
impoverished will greatly decrease the 
global burden of lung infections.
Lung Infections Threaten All 
Economic Groups
Among those who live in wealthy 
societies, infectious diseases cause less 
of a burden than do chronic diseases 
such as cancers and cardiovascular 
diseases. However, even among 
advantaged populations, lung 
infections are remarkably prominent. 
In the wealthiest as well as the poorest 
regions of the world, lung infections 
cause a greater burden than any other 
infectious disease (Figure 2). Thus, 
while climbing the socioeconomic 
ladder associates with a lesser burden, 
lung infections threaten across the 
economic spectra.
For those in wealthier populations, 
little further advancement is evident 
against lung infections. Focusing 
exclusively on the highest income 
populations (“Established Market 
Economies” or “High Income” groups 
in the WHO Burden of Disease Study), 
a comparison of the relative DALY 
losses due to lung infection shows little 
change from 1990 to 2002 (151 and 
137 DALYs lost/100,000 population, 
respectively), whereas there have been 
dramatic improvements in the burdens 
due to other diseases within these 
wealthy communities. For example, 
among the wealthiest populations, 
HIV in 2002 caused less than half the 
disease it did in 1990 (from 159 to 72 
DALYs lost/100,000 population). There 
are no DALY statistics available prior to 
1990, but other indicators such as the 
US mortality rate due to pneumonia 
and inﬂ  uenza suggest that, for wealthy 
countries, there has been little or no 
progress against lung infections since 
the ﬁ  rst half of the last century [6].
For several reasons, lung infections 
in wealthy countries seem poised 
to become even more of a concern 
in the near future. First, in these 
populations, advancing age makes lung 
infections increasingly more prevalent 
and life-threatening [7]. Therefore, 
demographic shifts resulting in an 
expanding elderly community within 
wealthy countries [8] suggest that more 
and more people are likely to suffer 
severely from lung infections. Second, 
novel respiratory infections emerge 
frequently, some of which can be highly 
virulent. Recent examples include 
SARS [9] and avian inﬂ  uenza [10]. If 
and when these new infections emerge, 
globalization increases the likelihood 
that such respiratory infections will 
become rapidly widespread [11]. 
Third, microbes that cause lung 
infections are increasingly resistant to 
previously effective antibiotics. While 
effective medical and public health 
practice will hopefully prevent the 
arrival of a “post-antibiotic” era [12], 
the continuously diminishing number 
of drugs effective against Streptococcus 
pneumoniae, Pseudomonas aeruginosa, and 
other common agents of community 
and hospital-acquired pneumonias 
raise concern.
Efforts and Resources Marshalled 
against Lung Infections
All diseases included in Figures 1 and 2, 
and many not listed, are critical targets 
of research and health care. All require 
more funding and more effort than 
they now receive. However, if some 
diseases (such as lung infections) are 
less widely recognized as critical threats 
to our health, then resources and 
efforts will be allocated suboptimally, 
DOI: 10.1371/journal.pmed.0030076.g002 
Figure 2. The Ten Leading Infections of the Poorest and Wealthiest Regions of the World
These leading infections are represented as a fraction of the total infectious disease burden of that 
region, and are in clockwise descending order. (STDs, sexually transmitted deseases excluding HIV)
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resulting in poorly tailored responses to 
public health needs.
Determining whether funds are 
contributing to research against a 
given disease is horribly inexact. 
Furthermore, the conceptual 
advances with most promise against 
a particular disease may more likely 
result from basic research than from 
disease-focused research. However, 
substantial resources are allocated to 
understanding and ﬁ  ghting particular 
diseases, and biomedical progress 
against those diseases is inﬂ  uenced 
by these targeted efforts. While the 
greatest burdens of disease and the 
greatest threats to the public health 
might be presumed to receive the 
greatest shares of research funding, 
they do not.
The US National Institutes of Health 
(NIH) spent approximately US$28 
billion on health-related research in 
2004 [13], of which US$287 million 
was allocated to lung infections. This 
is substantive and laudable, but it 
must be considered in perspective. It 
pales in comparison with the US$1.63 
billion spent on biodefense. More 
NIH money is spent on smallpox 
research (US$324 million) alone than 
on lung infection research. While it is 
essential to be proactive in recognizing, 
preventing, and preparing for looming 
or emerging threats to public health, it 
may be questioned whether funding for 
speculated risks should so overwhelm 
funding for diseases already causing 
such tremendous burdens.
Lung infection research is also 
poorly funded when compared with 
other currently signiﬁ  cant public 
health concerns. For example, 
US$2.85 billion were spent on HIV/
AIDS research, which is substantively 
improving prospects against this very 
important disease. It is remarkable, 
though, that lung infections cause a 
comparable or greater disease burden 
(Figures 1 and 2), yet they receive 
only one-tenth of HIV/AIDS research 
funding. In a similar vein, the NIH 
allocated comparable resources to lung 
infections as to sexually transmitted 
diseases (US$237 million), even though 
in wealthy countries such as the US 
lung infections cause seven times more 
disease than do sexually transmitted 
diseases (Figure 2), with even larger 
differentials in poorer countries. 
These ﬁ  gures from the NIH are but 
a few examples demonstrating that 
lung infections are relatively under-
represented.
Reacting to the pandemic threat of 
the recently emerging avian inﬂ  uenza 
virus (H5N1), the president of the 
US recently requested a lump sum 
totaling US$7.1 billion [14]. The 
majority of requested funds in the 
president’s plan, more than US$5.3 
billion, would be slated for the 
manufacture, purchase, and stockpile 
of vaccines and antivirals targeting 
inﬂ  uenza. An additional US$0.8 
billion would be allocated for research 
on new vaccines and antivirals against 
inﬂ  uenza, US$0.6 billion for inﬂ  uenza 
preparedness planning, and US$0.3 
billion to help countries detect and 
contain inﬂ  uenza outbreaks. It is this 
author’s opinion that the immediate 
need for such immense resources 
results from the potential of a severe 
inﬂ  uenza pandemic combined with 
many years of inadequate attention 
to lung infections. As of the time of 
writing this essay, the US Congress 
has yet to approve funding, and it 
remains unclear how much will be 
approved and how it will be deployed 
if approved, but a discrete set of 
funds may soon become available for 
ﬁ  ghting inﬂ  uenza speciﬁ  cally.
It is more difﬁ  cult to assess 
resources distributed by private 
organizations, but it is again 
evident that lung infections are 
underemphasized. U.S. News and 
World Report identiﬁ  es 20 charities 
as the largest to deal speciﬁ  cally 
with diseases and disease-related 
research [15]. Of these 20 leading 
charities, nine focus on cancer, two 
on organs (heart or kidney), two on 
classes of disease (mental illness or 
birth defects), and the rest on six 
speciﬁ  c diseases (muscular dystrophy, 
diabetes, multiple sclerosis, cystic 
ﬁ  brosis, Alzheimer disease, and 
arthritis). Perhaps the most prominent 
philanthropy focused speciﬁ  cally on 
infectious disease is The Global Fund 
to Fight AIDS, Tuberculosis, and 
Malaria [16]. This fund reports that it 
has attracted commitments of US$4.7 
billion from national governments, 
private companies, and other 
contributors for ﬁ  ghting these three 
speciﬁ  c diseases. Such philanthropies 
perform wonderful services in 
improving health. Lung infections 
would similarly beneﬁ  t from such a 
major philanthropic focus.
Infectious Disease through 
the Prism of Microbiology
Why does the consistent burden of lung 
infections receive so little attention? It 
may result in part from our tendency 
to view infectious diseases from a 
microbiology perspective. Microbes can 
reasonably be portrayed and perceived 
as enemies to be attacked and defeated. 
Smallpox eradication is a powerful 
illustration of the potential of such an 
approach. Because AIDS is caused by 
HIV, malaria by Plasmodia, tuberculosis 
by Mycobacteria, and so on, defeating 
HIV and Plasmodia and Mycobacteria 
are widely recognized as valid goals in 
virtually any informed community.
While the idea of ﬁ  ghting against 
a speciﬁ  c microbe is attractive, and 
such an “us-against-them” mentality is 
effective at mobilizing commitments, 
a microbe-speciﬁ  c focus is appropriate 
for some infectious diseases more than 
others. Lung infections do not result 
from one or a few extremely virulent 
microbes especially adapted to living in 
our lungs. Rather, a tremendous variety 
of microbes causes lung infections, 
and a strategy focused on the microbes 
is destined to be a game of catch-up. 
The physiology of breathing requires 
our lungs to be enormously exposed 
to microbes, both from the external 
environment (the air) and from a 
microbe-rich part of our own anatomy 
(our upper airways). It is inevitable that 
microbes land in our lungs. In part for 
these reasons, respiratory infections 
are common, and new respiratory 
pathogens are likely to emerge 
frequently. Eliminating microbes in the 
lungs requires inﬂ  ammatory responses 
that by their very nature compromise 
ventilation and blood-gas exchange. 
Thus, eliminating infection threatens 
physiology, and in part for this reason 
respiratory infections are often severe.
Tools are available for targeting 
some microbes causing lung infections 
(e.g., vaccines and antibiotics). 
Further research into reactive 
strategies directed speciﬁ  cally against 
individual microbes will likely 
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improve our abilities to prevent 
or cure select lung infections. Few 
and marginally effective tools are 
available for targeting exposures or 
host responses to lung infection (e.g., 
ultraviolet germicidal irradiation or 
corticosteroids, respectively). Forward-
thinking strategies might be directed 
at determinants of respiratory tract 
exposure, innate immune defenses 
against microbes in the lungs, and 
inﬂ  ammatory injury resulting from 
lung infection. Advances in these areas 
will provide opportunities both to 
combat ongoing public health crises 
and to limit the potential threat from 
emerging pathogens.
Conclusion
Like the proverbial elephant in the 
room, lung infections are a persistent 
problem not receiving the attention 
required. This may result in part from 
the nature of a disease lacking a single 
clear etiologic agent identiﬁ  ed as a 
microbiological enemy. Whatever the 
reasons, it means that an important 
cause of human suffering is relatively 
underserved. Because the burden of 
disease is so substantial, greater efforts 
designed to elucidate the biology of 
lung infections, to generate novel 
therapeutic or prophylactic strategies, 
and to better deliver interventions to 
needy populations have the potential 
for tremendous public health impact.  
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